Status:
UNKNOWN
Preconditioning Chemotherapy Combination With Cytokine Induced Killer Cell (CIK) Immunotherapy
Lead Sponsor:
Jinling Hospital, China
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
40-70 years
Brief Summary
This clinical Trial is proposed to explore whether preconditioning chemotherapy of Paclitaxel+cisplatin(TP)regimen combined with autologous adoptive CIK cell immunotherapy could benefit NSCLC patients...
Detailed Description
Lung cancer has become one of the leading causes of cancer related death, with increasing morbidity and mortality. And non small cell lung cancer (NSCLC) accounts for about 85% of all lung cancer pati...
Eligibility Criteria
Inclusion
- Primary non small cell lung cancer patients with pathology diagnosis with clinical TNM Classification of Malignant Tumours (TNM) stage (IIIa\~IV) can not accept operation or unwilling to operation;
- 40\~70 year old, Eastern Cooperative Oncology Group (ECOG) score ≤ 2 points, estimate survival \> 3 months;
- Blood White Blood Cell(WBC)≥ 4×109/L, Hb ≥ 100g/L, Platelet Count(PLT)≥ 80×109/L; Alanine aminotransferase(ALT) and aspartate aminotransferase(AST)≤ 2 times of normal upper value; Serum Cr ≤ 2 normal upper value;
- With more than one scalable lesions;
- Without any other malignant disease;
- Patients Voluntary attempt, and informed consent.
Exclusion
- Hypersusceptible to paclitaxel, cisplatin, CIK cells and IL-2;
- With no scalable lesions;
- Pregnant or lactating women;
- Uncontrolled brain metastasis with symptoms or with psychal problems can not describe subjective symptoms;
- With serious visceral organs failure;
- Patients with the conditions affect the administration, absorb, distribution, metabolism and excretion of the drugs;
- History of cardiovascular disease, including congestive heart failure, unstable angina patients, myocardial infarction; Cachexia; or other deadly diseases;
- Serious uncontrollable infection;
- At present Is receiving other cancer treatment (such as chemotherapy, radiation therapy, chemotherapy, immunosuppressants and thrombosis, targeted agents); Now or recently will join another experimental clinical study;
- Other situations that the researchers considered unsuitable for this study (such as mental illness, drug abuse, etc.).
Key Trial Info
Start Date :
June 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01902875
Start Date
June 1 2013
Last Update
July 18 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanjing General Hospital of Nanjing Military Command(Jinling Hospital)
Nanjing, Jiangsu, China, 210002